Compare CASH & NNNN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CASH | NNNN |
|---|---|---|
| Founded | 1954 | 2021 |
| Country | United States | Germany |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 1.5B |
| IPO Year | N/A | 2025 |
| Metric | CASH | NNNN |
|---|---|---|
| Price | $76.48 | $40.55 |
| Analyst Decision | Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $91.00 | N/A |
| AVG Volume (30 Days) | ★ 219.1K | 37.0K |
| Earning Date | 01-22-2026 | 04-28-2026 |
| Dividend Yield | ★ 0.27% | N/A |
| EPS Growth | ★ 9.29 | N/A |
| EPS | ★ 7.87 | 0.06 |
| Revenue | ★ $780,120,000.00 | $6,920,153.00 |
| Revenue This Year | $10.95 | N/A |
| Revenue Next Year | $4.75 | N/A |
| P/E Ratio | ★ $9.50 | $668.91 |
| Revenue Growth | ★ 5.66 | N/A |
| 52 Week Low | $64.45 | $5.18 |
| 52 Week High | $86.00 | $55.65 |
| Indicator | CASH | NNNN |
|---|---|---|
| Relative Strength Index (RSI) | 61.03 | N/A |
| Support Level | $73.08 | N/A |
| Resistance Level | $75.48 | N/A |
| Average True Range (ATR) | 1.67 | 0.00 |
| MACD | 0.14 | 0.00 |
| Stochastic Oscillator | 95.42 | 0.00 |
Pathward Financial Inc is a unitary savings and loan holding company. It's a wholly owned full-service banking subsidiary of Meta Financial, is both a community-oriented financial institution offering a variety of financial services to meet the needs of the communities it serves, and a payments company providing services on a nationwide basis. It operates through three reportable segments: Consumer: The Consumer segment includes the Partner Solutions business line, which collaborates with partners to navigate payment and lending needs; Commercial: The Commercial segment includes the Company's Commercial Finance business line, which helps businesses access funds needed to launch, operate, and grow; and Corporate Services. The majority of the revenue is generated from Consumer segment.
Anbio Biotechnology is a medical device company focused on in vitro diagnostics. It offers laboratory, wellness, at-home, and point-of-care (POCT) in vitro diagnostic (IVD) solutions to detect a wide range of biomarkers associated with critical medical domains encompassing infectious diseases, cancer, cardiovascular diseases, inflammation, drug abuse, endocrine disorders, renal disease, pharmacogenomics, and diabetes. Its product portfolio comprises AF-1200 Fluorescence Immunoassay Analyzer, SHA-100 Dry Chemistry Analyzer, Ferritin Rapid Test Kit, Dengue NS1 Rapid Test, Multi-HBV Rapid Test, COVID-19 Test Kit (Real-time PCR), and others. Geographically, the company generates maximum revenue from the European Union, followed by South America, Asia Pacific, North America, and other regions.